comparemela.com

Latest Breaking News On - மைக் ஹேண்ட்லி - Page 1 : comparemela.com

The cat came back: Canada s cougar comeback

The cat came back: Canada s cougar comeback
canadiangeographic.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canadiangeographic.ca Daily Mail and Mail on Sunday newspapers.

Cytocom, Inc Appoints Stephen Wilson, Ph D , as Head of Global Innovation

Share this article Share this article FORT COLLINS, Colo., April 20, 2021 /PRNewswire/  Cytocom, Inc. (Cytocom), a leading biopharmaceutical company creating next generation immune therapies built around proprietary discovery and development technologies, today announced that Stephen Wilson, Ph.D., has joined the company as its Head of Global Innovations, effective April 19, 2021. Dr. Wilson arrives at Cytocom after spending nearly 25 years at the La Jolla Institute for Immunology (LJII) where he was active in biomedical research and served as the research facility s chief operating officer. As Head of Global Innovation for Cytocom, Dr. Wilson will help identify new indications for Cytocom s existing pipeline of assets designed to rebalance the body s immune system and restore homeostasis and lead efforts to develop a global network of researchers and scientists to collaborate with Cytocom in new applications for its AIMS™ (Advanced Immunomodulating Multi-Receptor System) dr

Fort Collins soon-to-be newest public company looks to use opioid treatments to fight COVID, cancer – BizWest

FORT COLLINS A small pharmaceutical company that recently relocated to Fort Collins is betting that an anti-addiction medicine that’s been around for decades could be repurposed to fight COVID, cancer and spur a new wave of immunity-focused treatments. In a matter of months, Cytocom Inc. went from a startup with a stalled research portfolio into a company that is soon to become Northern Colorado’s newest public company through a reverse merger and with four conditions that its drug candidate is ready to begin pivotal Phase III trials. The company is helmed by CEO Mike Handley, a Colorado State University graduate who previously was chief executive for local pharmaceutical companies Armis Biopharma Inc. and Aletheia Therapeutics Corp. from 2012 to the fall of 2019.

Cytocom to Present at BIO CEO & Investor Digital Conference

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.